INMB

INmune Bio Inc. (INMB) | Rumor.io

INmune Bio

INMB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,584

Bullish sentiment (50-day avg)92%

Price to earnings ratio-1.08

Market capitalization55.5M

Earnings per share-0.62

Dividend yield (TTM)—

Revenue (annual)50K

Net income (annual)-45.9M

Social

What share of all stock conversation is about INMB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% -0.01

Jul 15

$INMB, a biotech stock, rose 11.5% in a significant reaction, with a study showing its XPro1595 drug prevents Alzheimer's pathology, memory loss, and pain.
A preclinical study published in a peer-reviewed journal demonstrated that XPro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain.
The stock's price target for tomorrow is mentioned, and some investors are optimistic about a potential violent squeeze if the price breaks above $2.15.

Generated by AI

Sentiment

Of the messages about INMB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	95.24% +4.76	78.31% +21.48
Bearish	—	—	4.76% -4.76	21.69% -21.48

Bullish· Jun 25

INmune Bio's MHRA approval of the Pediatric Investigational Plan (PIP) for CORDStrom is a significant milestone, demonstrating the company's progress in bringing its treatment to market.
The approval of the PIP for Ebstrocel in RDEB in the UK, along with the completion of the PIP review in under 3 months, highlights the company's efficient regulatory strategy and potential for a UK Marketing Authorization Application in 2026.
INmune Bio's stock is poised for a breakout above $1.50, potentially leading to a target price of $2.00 or higher, driven by increasing volume and a strong technical setup.

Bearish· Jun 25

The company has a high short ratio of 45% with only 3 days to cover, indicating a potential squeeze in the near future.
The asset has a significant amount of shares that are set to be dumped, with $65 million worth of shares already gone and more to come.
The company's recent price action is being driven by bots, with the author suggesting that the price movement is not based on fundamental analysis but rather on automated trading activity.

Generated by AI

Topics

Of the messages about INMB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	6.77%	5.43%
Technical Analysis	—	—	46.62%	1.04%
Macro	—	—	46.62%	47.03%
Analysts	—	—	0%	46.47%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.03%

Announcements· Aug 4

INmune Bio's Phase I/II trial of INKmune in metastatic castration-resistant prostate cancer met its primary and secondary endpoints and is now closed to enrollment.
The trial demonstrated an excellent safety profile and showed that INKmune was effective at activating NK cells in a subset of patients with advanced disease.
INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease, enabling a more robust measurement of the drug's effects and potential clinical benefits.

Technical Analysis· Jun 30

$INMB is a good entry below $3 with a bullish outlook.
The stock is due for a bounce over $3, with a potential squeeze as shorts availability is zero, and a stop loss at $1.89.
A break above $2 could lead to a short squeeze to $2.60-$2.75, with a key level to watch at $2.35-$2.40.

Generated by AI

Community

Of the messages about INMB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	30%	86.08%
Newcomers	—	—	70%	13.92%

Regulars· Aug 4

INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer has met endpoints and is closed to enrollment, with the next step being a Phase 2b trial in earlier-stage patients.
The complete float of INmune Bio's stock has been traded, with 14.9M shares traded in a single day, already surpassing the company's total shares outstanding.
INmune Bio's Phase I/II trial evaluating INKmune in Metastatic Castration-Resistant Prostate Cancer has met endpoints and is closed to enrollment, with the company also announcing a strong subgroup signal in the Phase 2 Alzheimer's data.

Newcomers· Aug 4

INmune Bio, Inc. (INMB) has announced the completion of its Phase I/II trial for INKmune in metastatic castration-resistant prostate cancer, with successful results.
The company's new NK cell therapy, INKmune, showed tumor shrinkage in late-stage prostate cancer trials, which could trigger a surprise move higher in the stock price.
INMB's clinical trial data was highly positive, with patients achieving remission, and the company is now trading like a controlled float play with a strong clinical tailwind.

Generated by AI

News

INmune Bio at H.C. Wainwright conference: rdeB drug nears filings

15d agoInvesting.com

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

16d agoYahoo Finance

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept. 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced their attendance at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16 at the Lotte New York Palace Hotel in New York City. David Moss, Founder and Chief Executive Officer, will be ho

21d agoYahoo Finance

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB)

INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis. Read more on INMB stock here.

1mo agoSeeking Alpha

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity BOCA RATON, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) ("INmune Bio" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it h

1mo agoYahoo Finance

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about INMB also mention

#	Name	Attention
1	TFFP - TFF Pharmaceuticals, Inc.	——
2	Coya Therapeutics, Inc.COYA	0%new
3	Annovis Bio, Inc.ANVS	0%0
4	Perma-Fix Environmental Services, Inc.PESI	0%0
5	Locafy LimitedLCFY	0%new
6	Alector Inc.ALEC	0%new
7	Anixa Biosciences, Inc.ANIX	0%new
8	Abivax SAABVX	0.01%-0.01
9	Spruce Biosciences, Inc.SPRB	0%0
10	Iridex Corp.IRIX	0%0

INmune Bio Inc.

Healthcare
Biotechnology

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform. The company’s programs are aimed at hematologic malignancies, solid tumors, chronic inflammation, and neurological conditions such as Alzheimer’s disease and treatment-resistant depression. INmune Bio Inc. works through a precision medicine approach, matching mechanisms of action to patient biology and clinical outcome measures. Headquartered in Boca Raton, Florida, the company operates in the biotechnology and immunology markets and focuses on advancing therapies that harness the body’s own immune response to fight disease.

Website

Location

225 NE Mizner Blvd.

Boca Raton, FL, 33432

United States

Social

What share of all stock conversation is about INMB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% -0.01

Jul 15

$INMB, a biotech stock, rose 11.5% in a significant reaction, with a study showing its XPro1595 drug prevents Alzheimer's pathology, memory loss, and pain.
A preclinical study published in a peer-reviewed journal demonstrated that XPro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain.
The stock's price target for tomorrow is mentioned, and some investors are optimistic about a potential violent squeeze if the price breaks above $2.15.

Generated by AI

Sentiment

Of the messages about INMB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	95.24% +4.76	78.31% +21.48
Bearish	—	—	4.76% -4.76	21.69% -21.48

Bullish· Jun 25

INmune Bio's MHRA approval of the Pediatric Investigational Plan (PIP) for CORDStrom is a significant milestone, demonstrating the company's progress in bringing its treatment to market.
The approval of the PIP for Ebstrocel in RDEB in the UK, along with the completion of the PIP review in under 3 months, highlights the company's efficient regulatory strategy and potential for a UK Marketing Authorization Application in 2026.
INmune Bio's stock is poised for a breakout above $1.50, potentially leading to a target price of $2.00 or higher, driven by increasing volume and a strong technical setup.

Bearish· Jun 25

The company has a high short ratio of 45% with only 3 days to cover, indicating a potential squeeze in the near future.
The asset has a significant amount of shares that are set to be dumped, with $65 million worth of shares already gone and more to come.
The company's recent price action is being driven by bots, with the author suggesting that the price movement is not based on fundamental analysis but rather on automated trading activity.

Generated by AI

Topics

Of the messages about INMB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	6.77%	5.43%
Technical Analysis	—	—	46.62%	1.04%
Macro	—	—	46.62%	47.03%
Analysts	—	—	0%	46.47%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.03%

Announcements· Aug 4

INmune Bio's Phase I/II trial of INKmune in metastatic castration-resistant prostate cancer met its primary and secondary endpoints and is now closed to enrollment.
The trial demonstrated an excellent safety profile and showed that INKmune was effective at activating NK cells in a subset of patients with advanced disease.
INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease, enabling a more robust measurement of the drug's effects and potential clinical benefits.

Technical Analysis· Jun 30

$INMB is a good entry below $3 with a bullish outlook.
The stock is due for a bounce over $3, with a potential squeeze as shorts availability is zero, and a stop loss at $1.89.
A break above $2 could lead to a short squeeze to $2.60-$2.75, with a key level to watch at $2.35-$2.40.

Generated by AI

Community

Of the messages about INMB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	30%	86.08%
Newcomers	—	—	70%	13.92%

Regulars· Aug 4

INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer has met endpoints and is closed to enrollment, with the next step being a Phase 2b trial in earlier-stage patients.
The complete float of INmune Bio's stock has been traded, with 14.9M shares traded in a single day, already surpassing the company's total shares outstanding.
INmune Bio's Phase I/II trial evaluating INKmune in Metastatic Castration-Resistant Prostate Cancer has met endpoints and is closed to enrollment, with the company also announcing a strong subgroup signal in the Phase 2 Alzheimer's data.

Newcomers· Aug 4

INmune Bio, Inc. (INMB) has announced the completion of its Phase I/II trial for INKmune in metastatic castration-resistant prostate cancer, with successful results.
The company's new NK cell therapy, INKmune, showed tumor shrinkage in late-stage prostate cancer trials, which could trigger a surprise move higher in the stock price.
INMB's clinical trial data was highly positive, with patients achieving remission, and the company is now trading like a controlled float play with a strong clinical tailwind.

Generated by AI

INmune Bio

Social

Jul 15

Bullish· Jun 25

Bearish· Jun 25

Announcements· Aug 4

Technical Analysis· Jun 30

Regulars· Aug 4

Newcomers· Aug 4

INmune Bio at H.C. Wainwright conference: rdeB drug nears filings

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB)

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

Also Discussed

INmune Bio Inc.

Company Information

Location

INmune Bio at H.C. Wainwright conference: rdeB drug nears filings

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB)

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Jul 15

Bullish· Jun 25

Bearish· Jun 25

Announcements· Aug 4

Technical Analysis· Jun 30

Regulars· Aug 4

Newcomers· Aug 4